Sun Pharmaceutical Reports Strong Financial Metrics and Record Dividend in June 2025

Sun Pharmaceutical Industries has reported its financial results for the quarter ending June 2025, showcasing notable developments in various operational metrics. The company's score has undergone an adjustment, reflecting a significant change in its evaluation over the past three months. Key highlights from the financial results indicate that Sun Pharma achieved its highest inventory turnover ratio at 5.08 times, demonstrating an effective strategy in managing inventory. Additionally, the operating cash flow reached a peak of Rs 4,198.77 crore, marking a robust generation of cash revenues from its business operations. The company also reported a record dividend per share of Rs 16.00, continuing its trend of increasing dividends over the past five years. Net sales for the quarter stood at Rs 13,851.40 crore, the highest in the last five quarters, suggesting a positive near-term sales trend. Furthermore, the operating profit reached Rs 4,301.66 crore, and the operating profit margin improved to 31.06%, indicating enhanced efficiency. Profit before tax, excluding other income, also hit a high of Rs 3,526.31 crore. Overall, Sun Pharmaceutical Industries is experiencing favorable trends in its financial metrics, contributing to the recent revision in its score. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.